Holen Sie sich die Stockscreener-App
122.97
0.10%
0.12
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Sanctuary Advisors LLC Buys 9,804 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Akari Therapeutics Names Interim CEO Patel as Permanent Chief, Adds Jazz Pharma Veteran to Board - StockTitan
Jazz Pharmaceuticals CEO to retire by end 2025, search begins - Investing.com Australia
Public Employees Retirement System of Ohio Makes New $2.49 Million Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals CEO to Present Strategic Vision at JP Morgan Healthcare Conference 2025 - StockTitan
Big Peninsula drugmaker on the hunt for new CEO - The Business Journals
Jazz Pharmaceuticals CEO to Retire, Succession Search Underway - Sleep Review
Graft-Versus-Host Disease Market on Track for Major Expansion - openPR
Jazz Pharmaceuticals Announces CEO Succession Plan - PharmiWeb.com
Jazz Pharmaceuticals CEO to retire - MSN
Bruce Cozadd to retire as Jazz’s CEO - BioCentury
Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025 - Marketscreener.com
Jazz Pharmaceuticals CEO to retire by end of 2025 - Investing.com South Africa
Jazz to search for new chief as CEO plans retirement - BioPharma Dive
Jazz Pharmaceuticals CEO to Step Down After Two Decades of Transformative Leadership - StockTitan
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock Position Raised by Franklin Resources Inc. - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Teachers Retirement System of The State of Kentucky - MarketBeat
Is Now The Time To Put Jazz Pharmaceuticals (NASDAQ:JAZZ) On Your Watchlist? - Yahoo Finance
Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch - Yahoo Finance
Morgan Stanley boosts Jazz Pharmaceuticals stock rating, sees upside with Ziihera launch - Investing.com Nigeria
Jazz Pharmaceuticals retains stock target, Overweight rating on FDA approval By Investing.com - Investing.com Nigeria
Morgan Stanley upgrades Jazz Pharmaceuticals shares, highlights Ziihera’s growth potential - Investing.com Nigeria
Morgan Stanley Upgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to "Overweight" - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - MarketBeat
State Street Corp Sells 71,036 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Y Intercept Hong Kong Ltd Reduces Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Stifel Financial Corp Has $15.83 Million Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Jane Street Group LLC - MarketBeat
Jazz Pharmaceuticals Showcases Evidence Reinforcing Epidiolex (CBD) Medical Benefits - Cannabis Business Times
Two Sigma Advisers LP Purchases 84,500 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements - Benzinga
XTX Topco Ltd Grows Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Price Target at $175.33 - MarketBeat
BNP Paribas Financial Markets Lowers Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Quantinno Capital Management LP Boosts Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Celebrating International Volunteers Day: Honoring the Impa - CSRwire.com
Jazz Pharma's Epidiolex Shows Remarkable 87% Seizure Reduction in Real-World Epilepsy Studies - StockTitan
Jazz (JAZZ) Up 3.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Point72 Asset Management L.P. Acquires 86,768 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Fmr LLC Reduces Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Bank of Montreal Can Sells 49,214 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Insider Sell: Bruce Cozadd Sells 2,000 Shares of Jazz Pharmaceuticals PLC - GuruFocus.com
Jazz Pharma's Groundbreaking Cancer Drug Ziihera Secures NCCN Guidelines Recognition After FDA Approval - StockTitan
Systematic Financial Management LP Purchases 29,647 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Centiva Capital LP - MarketBeat
Jazz Pharmaceuticals' chief accounting officer sells $6,491 in shares By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals CEO Bruce Cozadd sells $242,340 in shares By Investing.com - Investing.com Canada
Jazz Pharmaceuticals CEO Bruce Cozadd sells $242,340 in shares - Investing.com
Jazz Pharmaceuticals to Showcase Breakthrough Cancer Drug Ziihera Following FDA Approval - StockTitan
Parkman Healthcare Partners LLC Purchases New Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
JAZZJazz Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Jazz Pharmaceuticals plc to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting - Marketscreener.com
Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting - PR Newswire
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Short Interest Up 6.4% in November - MarketBeat
Point72 Asia Singapore Pte. Ltd. Raises Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by ARGA Investment Management LP - MarketBeat
Charles Schwab Investment Management Inc. Buys 42,587 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):